Ipca Laboratories Limited (IPCALAB.BO)
INR 1363.95
(4.85%)
INR 1363.95
(4.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 33.74 Billion INR | 24.46% |
| 2022 | 27.11 Billion INR | 30.17% |
| 2021 | 20.82 Billion INR | 54.02% |
| 2020 | 13.52 Billion INR | -16.46% |
| 2019 | 16.18 Billion INR | 14.58% |
| 2018 | 14.12 Billion INR | -1.12% |
| 2017 | 14.28 Billion INR | -5.02% |
| 2016 | 15.04 Billion INR | -7.86% |
| 2015 | 16.32 Billion INR | -15.34% |
| 2014 | 19.28 Billion INR | 54.15% |
| 2013 | 12.5 Billion INR | 9.42% |
| 2012 | 11.43 Billion INR | 6.51% |
| 2011 | 10.73 Billion INR | 24.68% |
| 2010 | 8.6 Billion INR | 14.89% |
| 2009 | 7.49 Billion INR | 1.17% |
| 2008 | 7.4 Billion INR | 30.45% |
| 2007 | 5.67 Billion INR | 31.14% |
| 2006 | 4.32 Billion INR | 18.52% |
| 2005 | 3.65 Billion INR | 1.24% |
| 2004 | 3.6 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -77.27 Billion INR | -329.0% |
| 2023 FY | 33.74 Billion INR | 24.46% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q4 | 33.74 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 38.22 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q4 | 27.11 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 27.11 Billion INR | 30.17% |
| 2022 Q2 | 20.39 Billion INR | 0.0% |
| 2021 Q4 | 20.82 Billion INR | 0.0% |
| 2021 FY | 20.82 Billion INR | 54.02% |
| 2021 Q2 | 14.97 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q1 | - INR | -100.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 13.52 Billion INR | -16.46% |
| 2020 Q4 | 13.52 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 15.04 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q4 | 16.18 Billion INR | 0.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 15.48 Billion INR | 0.0% |
| 2019 FY | 16.18 Billion INR | 14.58% |
| 2018 Q4 | 14.12 Billion INR | 0.0% |
| 2018 Q1 | - INR | 0.0% |
| 2018 FY | 14.12 Billion INR | -1.12% |
| 2017 FY | 14.28 Billion INR | -5.02% |
| 2016 FY | 15.04 Billion INR | -7.86% |
| 2015 FY | 16.32 Billion INR | -15.34% |
| 2014 FY | 19.28 Billion INR | 54.15% |
| 2013 FY | 12.5 Billion INR | 9.42% |
| 2012 FY | 11.43 Billion INR | 6.51% |
| 2011 FY | 10.73 Billion INR | 24.68% |
| 2010 FY | 8.6 Billion INR | 14.89% |
| 2009 FY | 7.49 Billion INR | 1.17% |
| 2008 FY | 7.4 Billion INR | 30.45% |
| 2007 FY | 5.67 Billion INR | 31.14% |
| 2006 FY | 4.32 Billion INR | 18.52% |
| 2005 FY | 3.65 Billion INR | 1.24% |
| 2004 FY | 3.6 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -107.344% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 77.831% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -551.292% |
| Granules India Limited | 22.95 Billion INR | -46.999% |
| Indoco Remedies Limited | 10.34 Billion INR | -226.26% |
| Achyut Healthcare Limited | 2.01 Million INR | -1676144.411% |
| Ajanta Pharma Limited | 10.71 Billion INR | -215.05% |
| Alkem Laboratories Limited | 48.6 Billion INR | 30.578% |
| Alpa Laboratories Limited | 307.12 Million INR | -10886.774% |
| Brooks Laboratories Limited | 248.6 Million INR | -13473.075% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -821.655% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -593.203% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -1500.056% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 68.455% |
| Eris Lifesciences Limited | 38.26 Billion INR | 11.825% |
| FDC Limited | 3.7 Billion INR | -809.704% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 48.176% |
| Gufic Biosciences Limited | 5.59 Billion INR | -502.57% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -1373.832% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -11270.4% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1034.626% |
| Lasa Supergenerics Limited | 541.92 Million INR | -6126.47% |
| Laurus Labs Limited | 42.71 Billion INR | 21.004% |
| Lupin Limited | 96.23 Billion INR | 64.938% |
| Mankind Pharma Limited | 23.87 Billion INR | -41.333% |
| Medicamen Biotech Limited | 940.36 Million INR | -3488.259% |
| Medico Remedies Limited | 438.24 Million INR | -7599.546% |
| Megasoft Limited | 1.85 Billion INR | -1720.842% |
| NATCO Pharma Limited | 10.53 Billion INR | -220.384% |
| Piramal Pharma Limited | 74 Billion INR | 54.404% |
| RPG Life Sciences Limited | 1.38 Billion INR | -2344.776% |
| Sigachi Industries Limited | 2.53 Billion INR | -1233.041% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 81.618% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -1558.751% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -2795.853% |
| Unichem Laboratories Limited | 8.06 Billion INR | -318.165% |
| Wanbury Limited | 3.15 Billion INR | -969.327% |
| Windlas Biotech Limited | 1.76 Billion INR | -1814.268% |
| ZIM Laboratories Limited | 2.08 Billion INR | -1521.656% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 52.999% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -766.778% |
| Divi's Laboratories Limited | 18.99 Billion INR | -77.687% |
| Hester Biosciences Limited | 3.59 Billion INR | -838.677% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1217.461% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -4204.895% |
| Bal Pharma Limited | 2.51 Billion INR | -1243.652% |
| Strides Pharma Science Limited | 37.68 Billion INR | 10.45% |
| Venus Remedies Limited | 1.39 Billion INR | -2322.659% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -308.969% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -200.789% |
| Shilpa Medicare Limited | 12.93 Billion INR | -160.915% |
| Aarti Drugs Limited | 11.5 Billion INR | -193.314% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -433.154% |
| Suven Life Sciences Limited | 148.62 Million INR | -22603.925% |
| Ind-Swift Limited | 13.45 Billion INR | -150.821% |
| Valiant Laboratories Limited | 1.05 Billion INR | -3088.52% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -215.118% |
| Solara Active Pharma Sciences Limited | 14.14 Billion INR | -138.57% |
| Themis Medicare Limited | 1.88 Billion INR | -1687.688% |
| Hikal Limited | 12.99 Billion INR | -159.662% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 58.875% |
| Sequent Scientific Limited | 8.27 Billion INR | -307.805% |
| Novartis India Limited | 1.8 Billion INR | -1773.455% |
| Wockhardt Limited | 39.87 Billion INR | 15.368% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 44.931% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -11583.835% |
| Neuland Laboratories Limited | 5.49 Billion INR | -513.666% |
| Morepen Laboratories Limited | 4.45 Billion INR | -656.601% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -5140.517% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -1607.363% |